Aviso de Derechos para emisoras del

FECHA: 11/09/2026

BOLSA MEXICANA DE VALORES, S.A.B DE C.V, INFORMA:

FOLIO DE REFERENCIA DEL EVENTO CORPORATIVO	296317
FOLIO DE REFERENCIA INDEVAL	940099C006
TIPO DE MENSAJE	Replace
COMPLETO / INCOMPLETO	COMPLETE
CONFIRMADO / NO CONFIRMADO	CONFIRMED

CLAVE DE COTIZACIÓN	ATAI
RAZÓN SOCIAL	ATAIBECKLEY INC.
SERIE	*
ISIN	US04650F1012
MERCADO PRINCIPAL	NASDAQ

TIPO DE EVENTO	MERGER

MANDATORIO / OPCIONAL / VOLUNTARIO	Mandatory
FECHA EFECTOS	14/09/2026

OPCIÓN	1
TIPO	CashAndSecurity
DEFAULT	true

TRANSACCIÓN	Cash Movement
CREDIT / DEBIT	Credit

TRANSACCIÓN	Securities Movement
CREDIT / DEBIT	Debit

VALORES A RECIBIR	
	US04650F1012
TRANSACCIÓN	Securities Movement
CREDIT / DEBIT	Credit

RATIO	NewToOld
	1 / 1
VALORES A RECIBIR	ExistingIssue
	US046CVR0150

NOTA
Holders will receive 6.75 USD and one Non-Tradable CVR per share.

NOTAS DEL EVENTO CORPORATIVO

NOTA

03/09/2026

USNASDAQ A Wednesday, September 2, 2026 Equity Corporate Actions Alert 2026 . 633 Information Regarding the Merger of AtaiBeckley Inc. (ATAI) At a special meeting to be held on September 8, 2026, the shareholders of AtaiBeckleyInc. (ATAI) will vote on the proposed merger with Eli Lilly And Co (LLY) The merger is tentatively scheduled to close prior to the market open on September 9, 2026. In anticipation of the closing, the stock will be halted immediately followingthe after.hours session at or around 7.50 p.m. on September 8, 2026. If the merger closes as anticipated,the stock will remain halted on the day of closing (September 9th) and will be suspended effective September 10, 2026. The details are as follows. Company Name Issue. AtaiBeckley Inc. Common Stock CUSIP . 04650F101 Symbol. ATAI Anticipated LastTrading Date. September 8, 2026 Anticipated Marketplace Effective Date for Suspension. September 10, 2026 Merger Consideration. USD6.75 incash plus one Contingent Value Right (CVR) for each share held. US SEC CA 0217 FORM 8.KATAIBECKLEY INC. As previously disclosed, AtaiBeckley Inc. (the Company) entered into an Agreement andPlan of Merger, dated as of July 15, 2026 (the Merger Agreement), with Eli Lilly and Company, an Indianacorporation (Parent) and AlbaliAcquisition Corporation, a Delawarecorporation and indirect wholly owned subsidiary of Parent (Merger Sub), pursuant to which Merger Subwill merge with and into the Company (the Merger), with the Company surviving as a wholly owned subsidiary of Parent. Capitalized terms used herein and not otherwise definedherein have the meanings set forthin the Merger Agreement. U.S. Antitrust Review The applicable waitingperiod under the Hart.Scott.RodinoAntitrust Improvements Act of 1976,as amended, in connection with theMerger expired at 11.59 p.m. Eastern Time on August 28, 2026. Other Regulatory Reviews On August 21, 2026, the Competition and Markets Authority in the United Kingdom responded to a briefing paper submitted byParent in respect of the Merger toindicate that it had, at such time, no further questions related to the Merger. Additionally, in connection with the Merger, on August 27,2026, the Australian Competition and Consumer Commission published itsdetermination that the Merger maybe consummated, subject to expiration of a 14.calendar day waiting period. The waiting period is scheduled to expire at 10.00 a.m. Eastern Time on September 10, 2026.US SEC CA 0084 ATAIBECKLEY INC SCHEDULE 14A Q. Am I entitled to appraisal rights under the DGCL A. Our stockholders and beneficial owners of our common stock are entitled, under certain circumstances, to seek appraisal of their sharesin connection with the merger under Delaware law. Pursuant to Section262(d) of the DGCL, this proxy statement serves as notice that recordor beneficial owners of our capital stock may be entitled to appraisal rights under Section 262 in connection with the merger. Under Section 262, if the merger is consummated, our stockholders (including beneficial owners of shares of our capital stock) will be entitled to seekappraisal of their shares if they (1) do not vote in favor of the adoption of the merger agreement (2)

properly demand appraisal of their shares (3) continuously hold of record or beneficially own their sharesthrough the effective date of the merger (4) otherwise comply with theprocedures of Section 262 and (5)do not withdraw their demands or otherwise lose their rights to appraisal. This means that these personswill be entitled to have their shares of our capital stock appraised by the Delaware Court of Chancery and to receive payment in cash of thefair value of their shares of ourcapital stock, exclusive of any elements of value arising from the accomplishment or expectation of the merger, together with (unless the Delaware Court of Chancery in its discretion determines otherwise for good cause shown) interest, if any, on the amount determined by the Delaware Court of Chancery to be the fair value from the effective date ofthe merger through the date of payment of the judgment at a rate of five percent over the Federal Reserve discount rate (including any surcharge) as established from time totime during the period between theeffective date of the merger and the date of payment of the judgment,compounded quarterly (except that,if at any time before the entry ofjudgment in the proceeding, the surviving corporation makes a voluntary cash payment to each person seeking appraisal, interest will accruethereafter only upon the sum of (x)the difference, if any, between the amount so paid and the fair valueof the shares as determined by theDelaware Court of Chancery and (y)interest theretofore accrued, unless paid at that time). The surviving corporation is under no obligation to make such voluntary cash payment prior to such entry of judgment.Due to the complexity of the appraisal process, persons who wish to seek appraisal of their shares are encouraged to seek the advice of legal counsel with respect to the exercise of appraisal rights. The DGCLrequirements for exercising appraisal rights are described in additional detail in this proxy statement,which description is qualified in its entirety by Section 262 regarding appraisal rights, available at the following URL, accessible withoutsubscription or cost, which is incorporated herein by reference. https. delcode. delaware.gov title8 c001sc09 index.html 262.US SEC CA 0038 FORM 8.K ATAIBECKLEY INC. Agreement and Plan of Merger On July 15, 2026, AtaiBeckleyInc. (the Company), entered into an Agreement and Plan of Merger (theMerger Agreement) with Eli Lillyand Company, an Indiana corporation(Parent), and Albali AcquisitionCorporation, a Delaware corporation and indirect wholly owned subsidiary of Parent (Merger Sub), pursuant to which, subject to satisfaction or waiver of the conditions therein, Merger Sub will merge with andinto the Company (the Merger), with the Company surviving as a wholly owned subsidiary of Parent. The Merger Agreement has been unanimously approved by the Company s board of directors (the Board). Pursuantto the Merger Agreement, and upon the terms and subject to the conditions thereof, at the effective timeof the Merger (the Effective Time)each share of the Company s commonstock, par value USD0.01 per share(the Common Stock), issued and outstanding immediately prior to theEffective Time (other than (x) shares held in the treasury of the Company, owned by the Company or any ofits subsidiaries, or owned by Parent, Merger Sub or any of their wholly owned subsidiaries, and (y) Dissenting Shares (as defined in the Merger Agreement)) will be convertedinto the right to receive (i) USD6.75 (the Closing Amount) per sharein cash, without interest, plus (ii) one contingent value right per share (each, a CVR and collectively,the CVRs), representing the rightto receive up to an aggregate of USD2.50 in cash per CVR upon achievement, if any, of specified clinicaland regulatory milestones, payablein accordance with the terms of a Contingent Value Rights Agreement (the CVR Agreement) to be entered into between Parent and a rights agent selected by Parent and reasonablyacceptable to the Company (the foregoing clauses (i) and (ii), collectively, the Merger Consideration),less any applicable tax withholding. Each CVR will entitle its holderto the following cash payments conditioned on achievement within specific time periods. (1) up to USD1.00 per share upon initiation of a Phase 3 clinical trial of VLS.01 prior to the 4th anniversary of the Closing (as defined in the Merger Agreement), (2) up to USD0.50 per shareupon U.S. regulatory approval andDrug Enforcement Agency (DEA) rescheduling of BPL.003 prior to the 5th anniversary of the Closing and (3) up to USD1.00 per share upon U.S. regulatory approva
(12/08/2026)

TERMS:
Edgar 8K July 16, 2026
Meeting Date September 8, 2026
On July 15, 2026, AtaiBeckley Inc., entered into an Agreement and Plan of Merger with Eli Lilly and Company, an Indiana corporation, and Albali Acquisition Corporation, a Delaware corporation and indirect wholly owned subsidiary of Parent, pursuant to which, subject to satisfaction or waiver of the conditions therein, Merger Sub will merge with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent. The Merger Agreement has been unanimously approved by the Company's board of directors.

Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, at the effective time of the Merger each share of the Company's common stock, par value USD0.01 per share, issued and outstanding immediately prior to the Effective Time (other than (x) shares held in the treasury of the Company, owned by the Company or any of its subsidiaries, or owned by Parent, Merger Sub or any of their wholly owned subsidiaries, and (y) Dissenting Shares (as defined in the Merger Agreement)) will be converted into the right to receive USD6.75 per share in cash, without interest, plus (ii) one contingent value right per share (each, a CVR and collectively, the CVRs), representing the right to receive up to an aggregate of USD2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, payable in accordance with the terms of a Contingent Value Rights Agreement (the CVR Agreement) to be entered into between Parent and a rights agent selected by Parent and reasonably acceptable to the Company (the foregoing clauses (i) and (ii), collectively, the Merger Consideration), less any applicable tax withholding. Each CVR will entitle its holder to the following cash payments conditioned on achievement within specific time periods: (1) up to USD1.00 per share upon initiation of a Phase 3 clinical trial of VLS-01 prior to the 4th anniversary of the Closing (as defined in the Merger Agreement), (2) up to USD0.50 per share upon U.S. regulatory approval and Drug Enforcement Agency (DEA) rescheduling of BPL-003 prior to the 5th anniversary of the Closing and (3) up to USD1.00 per share upon U.S. regulatory approval and DEA rescheduling of VLS-01 prior to the 7th anniversary of the Closing.

Contingent Value Rights Agreement
In connection with the Merger, at or immediately prior to the Effective Time, Parent will execute and deliver the CVR Agreement with a rights agent. Under the CVR Agreement, each CVR will represent the contractual right to receive a contingent cash payment upon the achievement of certain specified milestones. The CVRs will not be transferable (except in limited circumstances), will not be registered under the Securities Act of 1933, as amended (the Securities Act), or the Securities Exchange Act of 1934, as amended (the Exchange Act), will not be listed on any securities exchange, and will not have any voting or dividend rights. The CVRs will not represent any equity or ownership interest in Parent, the Company, or the surviving corporation.